MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$4,636,649
Free Cash flow
-$4,031,226
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Depreciation and amortization
Proceeds from the purchase of st...
Others
Negative Cash Flow Breakdown
Net loss
Payments of stock issuance costs
Payments on obligations under fi...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-5,667,525
-5,465,751
-5,469,446
25,411,055
Depreciation and amortization
946,370
956,401
964,422
960,850
Non-cash lease expense, net of lease payments
-11,751
-19,553
-2,301
2,842
Share-based payments for services
155,735
57,106
58,318
167,388
Equity based compensation
454,094
451,381
443,275
440,506
Common stock contributed to 401 plan
60,556
61,788
57,262
53,807
Shares issued for settlement of clinic development costs
-
-
-
350,885
Shares issued for settlement of clinical development costs
0
431,663
-302,758
-
Loss on patent impairment
0
22,257
12,851
4,963
Prepaid expenses
-12,187
199,111
183,258
28,676
Supplies used for r&d and manufacturing
18,878
26,905
-55,677
-350,834
Deposits
0
-720
0
7,585
Accounts payable
-11,458
-101,031
71,171
-445,154
Accrued expenses
-7,099
-26,240
-226,360
181,218
Due to employees
33,041
-202,780
143,555
-252,932
Net cash used in operating activities
-4,031,226
-4,022,389
-4,022,105
-4,670,523
Purchases of property and equipment
0
0
0
5,155
Expenditures for patent costs
-
-
-
0
Net cash used in investing activities
0
0
0
-5,155
Proceeds from issuance of common stock and pre-funded warrants
9,700,000
0
0
15,730,800
Proceeds from related party loans
-
-
-
0
Payments of stock issuance costs
935,505
0
158,115
1,594,947
Payments of related party loans
-
-
-
0
Proceeds from the purchase of stock by officers and directors
479,000
200,001
49,999
-
Proceeds from notes payable
0
-
-
0
Proceeds from the purchase of stock by officers and directors
-
-
-
-219,995
Payments of notes payable
0
-
-
0
Payments on obligations under finance leases
575,620
564,462
545,657
519,566
Net cash (used in) provided by financing activities
8,667,875
-364,461
-653,773
13,836,282
Net decrease in cash and cash equivalents
4,636,649
-4,386,850
-4,675,878
9,160,604
Cash and cash equivalents, beginning of period
6,277,582
6,277,582
10,953,460
4,738,173
Cash and cash equivalents, end of period
6,527,381
1,890,732
6,277,582
10,953,460
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$9,700,000
(-22.77%↓ Y/Y)
Proceeds from the
purchase of stock by...
$479,000
Net cash (used in)
provided by financing...
$8,667,875
(-9.11%↓ Y/Y)
Canceled cashflow
$1,511,125
Net decrease in cash
and cash...
$4,636,649
(257.42%↑ Y/Y)
Canceled cashflow
$4,031,226
Payments of stock
issuance costs
$935,505
(-38.93%↓ Y/Y)
Payments on obligations
under finance leases
$575,620
(-61.41%↓ Y/Y)
Depreciation and
amortization
$946,370
(-67.64%↓ Y/Y)
Equity based
compensation
$454,094
(-69.12%↓ Y/Y)
Share-based payments for
services
$155,735
(-73.48%↓ Y/Y)
Common stock
contributed to 401 plan
$60,556
(-63.19%↓ Y/Y)
Due to employees
$33,041
(-95.90%↓ Y/Y)
Prepaid expenses
-$12,187
(-187.84%↓ Y/Y)
Non-cash lease expense,
net of lease...
-$11,751
(-495.66%↓ Y/Y)
Net cash used in
operating activities
-$4,031,226
(67.62%↑ Y/Y)
Canceled cashflow
$1,673,734
Net loss
-$5,667,525
(70.65%↑ Y/Y)
Supplies used for r&d and
manufacturing
$18,878
(103.03%↑ Y/Y)
Accounts payable
-$11,458
(-568.82%↓ Y/Y)
Accrued expenses
-$7,099
(88.26%↑ Y/Y)
Buy us a coffee
CEL SCI CORP (CVM)
CEL SCI CORP (CVM)